Profound Medical Corp. (TSX:PRN)

Market Cap	297.97M +5.3%
Revenue (ttm)	22.07M +50.7%
Net Income	-58.37M
EPS	-1.93
Shares Out	36.29M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,089
Average Volume	19,505
Open	9.03
Previous Close	9.09
Day's Range	8.19 - 9.07
52-Week Range	5.23 - 12.40
Beta	0.47
RSI	45.95
Earnings Date	May 7, 2026

About Profound Medical

Profound Medical Corp. operates as a commercial-stage medical device company that develops and markets AI-powered, MRI-guided, incision-free therapeutic systems for the image guided ablation of diseased tissue. The company’s lead product TULSA-PRO system combines magnetic resonance imaging (MRI), robotically driven transurethral sweeping action/thermal ultrasound and closed-loop temperature feedback control to ablate whole gland or physician defined region of malignant or benign prostate tissue. It also provides Sonalleve, which combines real-t...

• Industry: Medical Devices
• Sector: Healthcare
• CEO: Arun Menawat
• Employees: 162
• Stock Exchange: Toronto Stock Exchange
• Ticker Symbol: PRN

Financial Performance

In 2025, Profound Medical's revenue was $16.10 million, an increase of 50.73% compared to the previous year's $10.68 million. Losses were -$42.57 million, 53.0% more than in 2024.

Financial numbers in USD